Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24380347 | 0.92 | OPRM1 (0.42) | OPRM1OPRK1OPRL1OPRD1ATM | |
| SCHEMBL10821867 | 0.77 | OPRM1 (0.56) | OPRM1OPRK1OPRL1OPRD1DRD3 | |
| SCHEMBL14899046 | 0.72 | OPRM1 (0.56) | OPRM1OPRK1OPRL1OPRD1DRD3 | |
| SCHEMBL5736771 | 0.72 | CYP2A6 (0.32) | OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL28097036 | 0.72 | SLC6A4 (0.42) | OPRM1OPRK1OPRL1OPRD1DRD3 | |
| SCHEMBL10603880 | 0.72 | OPRM1 (0.59) | OPRM1OPRK1OPRL1OPRD1DRD3 | |
| SCHEMBL791817 | 0.72 | SLC6A4 (0.47) | OPRM1OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10605630 | 0.71 | DRD3 (0.37) | OPRM1OPRK1OPRL1OPRD1DRD3 | |
| SCHEMBL1040389 | 0.71 | OPRM1 (0.54) | OPRM1OPRK1OPRL1OPRD1DRD3 | |
| SCHEMBL1040539 | 0.71 | OPRM1 (0.54) | OPRM1OPRK1OPRL1OPRD1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | OPRM1 69/4885OPRK1 85/4885OPRL1 36/4885 |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | OPRM1 69/4885OPRK1 85/4885OPRL1 36/4885 |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | OPRM1 69/4885OPRK1 85/4885OPRL1 36/4885 |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | OPRM1 69/4885OPRK1 85/4885OPRL1 36/4885 |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | OPRM1 69/4885OPRK1 85/4885OPRL1 36/4885 |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | OPRM1 69/4885OPRK1 85/4885OPRL1 36/4885 |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | OPRM1 69/4885OPRK1 85/4885OPRL1 36/4885 |
| US-10981894-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | OPRM1 69/4885OPRK1 85/4885OPRL1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.